ACT-2 Randomised study comparing 6 cycles of chemotherapy with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day intervals (CHOP-14), both with or without the monoclonal anti-CD52 antibody alemtuzumab in patients aged 61 to 80 years with T-cell-Lymphoma DSHNHL 2006-1B (ACT-2) years months Therapy arm Gender Age (years) IPI factor age>60 years IPI factor LDH>N IPI factor ECOG>1 IPI factor stage III/IV IPI factor extralymphatic involvement > 1 IPI score Extralymphatic involvement Bulky disease B-symptoms Bone marrow involvement Reference pathology diagnosis Event-free survival (months) Event-free survival status Progression-free survival (months) Progression-free survival status Overall survival (months) Overall survival status 6 x CHOP-14 6 x A-CHOP-14 male female age <= 60 years age > 60 years LDH <= N LDH > N ECOG <= 1 ECOG > 1 stage I/ II stage III/ IV E <= 1 E > 1 no yes no yes no yes no yes no T-cell T-cell lymphoma, specification of subtype not possible Peripheral T-cell lymphoma, unspecified (PTCL-NOS) Angioimmunoblastic T-cell lymphoma (AILT) Anaplastic large cell lymphoma, ALK-negative Extranodal NK/T-cell lymphoma,nasal type Enteropathy-type T-cell lymphoma Other T-cell T-zone variant Perifollicular variant Follicular variant censored event censored event censored event